English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThree currently circulating omicron subvariants of SARS-CoV-2 – including two that currently make up almost 50% of reported COVID-19 infections in the U.S. – are better at evading vaccine- and infection-generated neutralizing antibodies than earlier versions of omicron, new research suggests.
Tag: neutralizing antibodies
Neutralizing antibodies from single COVID-19 booster steadily decline
Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests.
Scientists develop effective intranasal mumps-based COVID-19 vaccine candidate
New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.
COVID booster needed for broad protection against omicron variants
A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.
These fridge-free COVID-19 vaccines are grown in plants and bacteria
Nanoengineers at the University of California San Diego have developed COVID-19 vaccine candidates that can take the heat. Their key ingredients? Viruses from plants or bacteria.
Study shows neutralizing antibodies to SARS-CoV-2 remain relatively high for up to 13 months following infection
New York, NY – Researchers from the Icahn School of Medicine at Mount Sinai have found that most COVID-19 patients have persistent antibodies to the SARS-CoV-2 virus at levels that are correlated with neutralization of the virus more than…
Genetics May Play Role in Determining Immunity to COVID-19
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
Story Tips from Johns Hopkins Experts on COVID-19
Vaccines take time to work. After getting a COVID-19 vaccine, it takes a while for the immune system to fully respond and provide protection from the virus. For the Moderna and Pfizer COVID-19 vaccines, it takes up to two weeks after the second shot to become appropriately protected.
GenScript Granted Authorization for cPass™ SARS-CoV-2 Neutralization Antibody Detection Test in Brazil
GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil’s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.
Key details about broadly neutralizing antibodies provide insights for universal flu vaccine
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
Researchers develop new tools to rapidly test activity of anti-coronavirus antibodies
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.